Artificial Intelligence in Urooncology: What We Have and What We Expect

被引:7
|
作者
Fron, Anita [1 ]
Semianiuk, Alina [1 ]
Lazuk, Uladzimir [1 ]
Ptaszkowski, Kuba [2 ]
Siennicka, Agnieszka [3 ]
Leminski, Artur [4 ]
Krajewski, Wojciech [1 ]
Szydelko, Tomasz [1 ]
Malkiewicz, Bartosz [1 ]
机构
[1] Wroclaw Med Univ, Univ Ctr Excellence Urol, Dept Minimally Invas & Robot Urol, PL-50556 Wroclaw, Poland
[2] Wroclaw Med Univ, Dept Physiotherapy, PL-50368 Wroclaw, Poland
[3] Wroclaw Med Univ, Dept Physiol & Pathophysiol, PL-50556 Wroclaw, Poland
[4] Pomeranian Med Univ, Dept Urol & Urol Oncol, PL-70111 Szczecin, Poland
关键词
artificial intelligence; machine learning; urooncology; prostate cancer; RENAL-CELL CARCINOMA; PROSTATE-CANCER; TEXTURE ANALYSIS; MACHINE; DIAGNOSIS; RADIOMICS; PREDICTION; BIOPSIES; MODELS; TUMORS;
D O I
10.3390/cancers15174282
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Our study provides an overview of the current state of artificial intelligence applications in urooncology and explores potential future advancements in this field. With remarkable progress already achieved, artificial intelligence has revolutionized urooncology by facilitating image analysis, grading, biomarker research, and treatment planning. We also discuss types of artificial intelligence and their possible applications in the management of cancers such as prostate, kidney, bladder, and testicular. As artificial intelligence technology continues to evolve, it holds immense promise for further advancing urooncology and enhancing the care of patients with cancer.Abstract Introduction: Artificial intelligence is transforming healthcare by driving innovation, automation, and optimization across various fields of medicine. The aim of this study was to determine whether artificial intelligence (AI) techniques can be used in the diagnosis, treatment planning, and monitoring of urological cancers. Methodology: We conducted a thorough search for original and review articles published until 31 May 2022 in the PUBMED/Scopus database. Our search included several terms related to AI and urooncology. Articles were selected with the consensus of all authors. Results: Several types of AI can be used in the medical field. The most common forms of AI are machine learning (ML), deep learning (DL), neural networks (NNs), natural language processing (NLP) systems, and computer vision. AI can improve various domains related to the management of urologic cancers, such as imaging, grading, and nodal staging. AI can also help identify appropriate diagnoses, treatment options, and even biomarkers. In the majority of these instances, AI is as accurate as or sometimes even superior to medical doctors. Conclusions: AI techniques have the potential to revolutionize the diagnosis, treatment, and monitoring of urologic cancers. The use of AI in urooncology care is expected to increase in the future, leading to improved patient outcomes and better overall management of these tumors.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] Artificial Intelligence Applications in Diabetic Retinopathy: What We Have Now and What to Expect in the Future
    Kong, Mingui
    Song, Su Jeong
    ENDOCRINOLOGY AND METABOLISM, 2024, 39 (03) : 416 - 424
  • [2] Artificial intelligence in orthopaedics What can we expect?
    Mathis, Dominic
    Ackermann, Jakob
    Guenther, Daniel
    Laky, Brenda
    Deichsel, Adrian
    Schuettler, Karl Friedrich
    Wafaisade, Arasch
    Eggeling, Lena
    Kopf, Sebastian
    Muench, Lukas
    Herbst, Elmar
    ARTHROSKOPIE, 2024, 37 (01) : 52 - 64
  • [3] What did we expect? What have we reached?
    Steenfeldt-Foss, O
    NORDIC JOURNAL OF PSYCHIATRY, 1998, 52 : 59 - 60
  • [4] VCSELs in '98: What we have and what we can expect
    Coldren, LA
    Hegblom, ER
    Akulova, YA
    Ko, J
    Strzelecka, EM
    Hu, SY
    VERTICAL-CAVITY SURFACE-EMITTING LASERS II, 1998, 3286 : 2 - 16
  • [5] Artificial intelligence in GI pathology: where are we today and what can we expect
    von Loga, Katharina
    JOURNAL OF PATHOLOGY, 2024, 264 : S57 - S57
  • [6] Therapeutic medications against diabetes: What we have and what we expect
    Hu, Cheng
    Jia, Weiping
    ADVANCED DRUG DELIVERY REVIEWS, 2019, 139 : 3 - 15
  • [7] The Fontan circulation: What have we learned? What to expect?
    de Leval, MR
    PEDIATRIC CARDIOLOGY, 1998, 19 (04) : 316 - 320
  • [8] The Fontan Circulation: What Have We Learned? What to Expect?
    M.R. de Leval
    Pediatric Cardiology, 1998, 19 : 316 - 320
  • [9] Artificial intelligence in diabetes mellitus and endocrine diseases — what can we expect?
    Ioannis T. Oikonomakos
    Charlotte Steenblock
    Stefan R. Bornstein
    Nature Reviews Endocrinology, 2023, 19 : 375 - 376
  • [10] Artificial intelligence in diabetes mellitus and endocrine diseases - what can we expect?
    Oikonomakos, Ioannis T.
    Steenblock, Charlotte
    Bornstein, Stefan R.
    NATURE REVIEWS ENDOCRINOLOGY, 2023, 19 (07) : 375 - 376